Sabinsa's flagship combination product, Curcumin C3 Complex® with BioPerine® (525mg/2.5 mg twice a day, 14 days), was used as adjuvant therapy for COVID-19 in a double-blind, randomized controlled clinical trial conducted on COVID-19 patients in India, where the wide-spread virus infection has strained the healthcare system.
Court Orders Prakruti to Pay over $1 Million in Fees and Costs to Sabinsa as a Sanction For Discovery Abuses in Litigation
- Details
- Press Release
- 359
Sami-Sabinsa Group Limited, the world leader in Curcumin for the dietary supplements industry, has been awarded more than $1 Million in attorney’s fees and costs against Prakruti Products. The award, issued by a federal judge in New Jersey on May 24, came in the wake of Sabinsa’s successful prosecution of Prakruti’s egregious discovery misconduct. The Magistrate Judge had previously imposed non-monetary sanctions on Prakruti, and that ruling was affirmed by the District Judge on appeal. The award is Sabinsa’s latest win in a years-long discovery battle with Prakruti that began in June 2017, after the Court reopened a settled case involving Prakruti’s infringement of Sami-Sabinsa’s patented Curcumin C3 Complex®.
Sabinsa Founder Dr. Muhammed Majeed Named Father of Indian Nutraceuticals Industry by ASSOCHAM
- Details
- Press Release
- 197
Dr. Muhammed Majeed, founder of the Sami-Sabinsa Group, was named the Father of Indian Nutraceuticals Industry with an honorary award presented on the occasion of ASSOCHAM’s virtual conference entitled Efficacy of Herbal Nutraceuticals: Stimulating the New Lifestyle.
New Research Published on Sabinsa’s Curcumin C3 Reduct® Supports Efficacy as an Oral Care Ingredient
- Details
- Press Release
- 393
